Clinic to Community Navigation to Improve Diabetes Outcomes (CCN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03474731|
Recruitment Status : Recruiting
First Posted : March 23, 2018
Last Update Posted : November 11, 2021
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus||Behavioral: Diabetes Self Management Program Behavioral: Tailored Patient Navigation (PN) only Behavioral: DSMP AND Tailored Patient Navigation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1200 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Background and justification: Nearly 29 million Americans (9.3% of the population) have type 2 Diabetes Mellitus (T2DM) and another 86 million are considered prediabetic, 20-30% of whom will develop diabetes within five years.4,5 T2DM disproportionately affects those from lower socioeconomic status (SES) and rural backgrounds. Appalachian residents represent an extreme version of this already vulnerable population, with rates of diabetes 46% higher than national averages.6,7 We have developed, pilot tested (N=41) and refined (N=48 in-depth interviews, 4 focus groups with 31 participants, and 2 CAB meetings with 16 members), a culturally appropriate, feasible, and promising intervention that combines diabetes self-management education and tailored patient navigation intervention.|
|Masking:||None (Open Label)|
|Official Title:||Clinic to Community Navigation to Improve Diabetes Outcomes|
|Actual Study Start Date :||April 29, 2018|
|Estimated Primary Completion Date :||November 2023|
|Estimated Study Completion Date :||November 2024|
Experimental: Diabetes Self Management Program only
group education classes of the Diabetes Self-Management Program, (DSMP)
Behavioral: Diabetes Self Management Program
Diabetes Self Management Program (DSMP) in a group setting: The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).
Groups randomized to one of two arms (DSMP only and CCN) will receive the DSMP. The DSMP has demonstrated significant improvements in communication with physicians, healthy eating, and hypoglycemia at six and twelve months. The DSMP and other self-management programs have been shown to increase self-efficacy, knowledge, and skill building; ensure accountability/monitoring; improve patient-provider interaction; leverage local assets; address sustainability, and be cost effective.
Experimental: Tailored Patient Navigation (PN) only
assisting patients in navigation to physician offices, allowing for standard of care to follow.
Behavioral: Tailored Patient Navigation (PN) only
Tailored Patient Navigation (PN) only: The goal of this arm of the project is to try to get participants to attend their recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs. We will have to add an additional eligibility criterion for this group-they have to be out of compliance with medical appointments. Most participants will need PN services, owing to missed, rescheduled, or infrequent appointments. This means not attending their office visits, as recommended, which typically is every 3 months. We will interact with them to verify attendance and, at times, to access patient medical records if needed.
Experimental: DSMP AND Tailored Patient Navigation
Both group education classes and patient navigation
Behavioral: DSMP AND Tailored Patient Navigation
DSMP AND Tailored Patient Navigation : Both group education classes and patient navigation
- Hemoglobin A1c [ Time Frame: Baseline to 18 months ]Changes in hemoglobin A1c (HbA1c) will be measured with a Bayer DCA 2000+ Analyzer (21), which has a test coefficient of variation < 5% consistent with requirements of the National Diabetes Data Group.
- Body mass index [ Time Frame: Baseline to 18 months ]Change in calculated as a change in weight in kilograms divided by the square of height in meter.
- Waist circumference [ Time Frame: Baseline to 18 months ]Change in Waist circumference at the umbilical waist using the Tech-Med model cat. no. 4414.
- Clinic attendance [ Time Frame: Baseline to 18 months ]Data will be collected from clinic staff regarding participant clinic visit attendance
- Health related quality of life survey (HRQOL) [ Time Frame: Baseline to 18 months ]Changes in sociodemographics, health status and behavior, self-perceived health status, function, depression, diabetes empowerment scale, patient activation, T2DM self-management knowledge, health-related quality of life will be assessed and reported as a single HRQOL score
- Systolic blood pressure [ Time Frame: Baseline to 18 months ]Change in systolic blood pressure will be reported as the average of two sphygmomanometer readings
- Diastolic blood pressure [ Time Frame: Baseline to 18 months ]Change in diastolic blood pressure will be reported as the average of two sphygmomanometer readings
- High density lipoprotein (HDL) [ Time Frame: Baseline to 18 months ]blood will be drawn and HDL will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in HDL over 18 months
- Low density lipoprotein (LDL) [ Time Frame: Baseline to 18 months ]blood will be drawn and LDL will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in LDL over 18 months
- Total cholesterol [ Time Frame: Baseline to 18 months ]blood will be drawn and Total cholesterol will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in total cholesterol over 18 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03474731
|Contact: Jennifer Malan||606 633 email@example.com|
|United States, Kentucky|
|University of Kentucky||Recruiting|
|Lexington, Kentucky, United States, 40536|
|Contact: Nancy Schoenberg, PhD 859-323-8175 firstname.lastname@example.org|
|Contact: Jennifer Malan 859 633-3339 email@example.com|
|Principal Investigator: Nancy Schoenberg, PhD|
|Sub-Investigator: Laura Hieronymus, DNP|
|Sub-Investigator: Roberto Cardarelli|
|Sub-Investigator: Brittany Smalls, PhD, MHSA|
|Sub-Investigator: Frances Feltner, DNP|
|Sub-Investigator: Glen Mays|
|Sub-Investigator: Richard Charnigo, PhD|
|Principal Investigator:||Nancy Schoenberg, PhD||University of Kentucky|